title: [Quantitative analysis of Sokal's risk index in relation to 2 therapy protocols: their respective impact on clinical remission of chronic myeloid leukemia].
abstract: OBJECTIVE
  To quantitatively evaluate the impact of Sokal's risk index and that of 2 therapy protocols on the clinical outcome of patients with chronic myeloid leukemia (CML).
  
  
  METHODS
  With the assistance of Access 2000 database of CML, 94 patients with CML were grouped on the basis of either different therapy protocols utilizing harringtonine plus Ara-C (HA) vs hydroxyurea (Hu) or Sokal scores, and the impact of therapy protocol and risk profile were quantitatively evaluated respectively.
  
  
  RESULTS
  Treatment protocol utilizing HA was incapable of lengthening the duration of chronic phase (DCP) of CML, regardless of its better short-term effect than that of Hu. The impact of risk profile of the patients on clinical remission rate and DCP was more significant than that of the therapy protocols.
  
  
  CONCLUSIONS
  HA should not be used as the first-line protocol in the treatment of CML patients in chronic phase who have not received any previous medical intervention. Patients should be categorized according to the risk profile for choosing appropriate treatment protocol and making better clinical judgement.
authors.affiliation: Department of Hematology, Nanfang Hospital, First Military Medical University, Guanghou 510515, China.
authors.forename: Qing-Feng
authors.initials: QF
authors.lastname: Du
authors.forename: Xiao-Li
authors.initials: XL
authors.lastname: Liu
authors.forename: Qi-Fa
authors.initials: QF
authors.lastname: Liu
authors.forename: Rong
authors.initials: R
authors.lastname: Li
authors.forename: Qi
authors.initials: Q
authors.lastname: Chen
authors.forename: Shu-Yun
authors.initials: SY
authors.lastname: Zhou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D005260:Female; D006248:Harringtonines / Q000627:therapeutic use*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D006248:Harringtonines; D003561:Cytarabine; C062500:harringtonin